17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells

Archives of Virology

Volumn 157, Issue 10, 2012, Pages 1971-1974

  Evers, David L ^a,c   Chao, Chih Fang ^a   Zhang, Zhigang ^a   Huang, Eng Shang ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN HERPESVIRUS 5;

EID: 84867141773     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1379-7     Document Type: Article

References (29)

1. Mocarski Jr ES, Shenk TM, Pass RF (2007) Cytomegaloviruses. In: Knipe DM, Howley PM (eds) Field's virology, 5th Edn. Lippincott Williams & Wilkins, Philadelphia, pp 2701-2772.
2. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A, Transplantation Society International CMV Consensus Group (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89: 779-795.
3. Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23: 689-712.
4. Prichard MN, Kern ER (2011) The search for new therapies for human cytomegalovirus infections. Virus Res 157: 212-221.
5. Gao Z, Garcia-Echeverria C, Jensen MR (2010) Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 13: 193-202.
6. Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42: 273-279.
7. Li YH, Tao PZ, Liu YZ, Jiang JD (2004) Geldanamycin, a ligand of heat shock protein 90, inhibits the replication of herpes simplex virus type 1 in vitro. Antimicrob Agents Chemother 48: 867-872.
8. De Bolle L, Andrei G, Snoeck R, Zhang Y, van Lommel A, Otto M, Bousseau A, Roy C, De Clercq E, Naesens L (2004) Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochem Pharmacol 67: 325-336.
9. Basha W, Kitagawa R, Uhara M, Imazu H, Uechi K, Tanaka J (2005) Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus. Antivir Chem Chemother 16: 135-146.
10. Huang E-S, Chen ST, Pagano JS (1973) Human cytomegalovirus. I. Purification and characterization of viral DNA. J Virol 12: 1473-1481.
11. Mar EC, Cheng YC, Huang E-S (1983) Effect of 9-(1, 3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother 24: 518-521.
12. Kowalik TF, Wing B, Haskill JS, Azizkhan JC, Baldwin AS Jr, Huang E-S (1993) Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection. Proc Natl Acad Sci USA 90: 1107-1111.
13. Prichard MN, Turk SR, Coleman LA, Engelhardt SL, Shipman C Jr, Drach JC (1990) A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J Virol Methods 28: 101-106.
14. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang E-S (2003) Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424: 456-461.
15. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN (2003) Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 102: 269-275.
16. Johnson RA, Wang X, Ma XL, Huong SM, Huang E-S (2001) Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 75: 6022-6032.
17. Johnson RA, Ma XL, Yurochko AD, Huang E-S (2001) The role of MKK1/2 kinase activity in human cytomegalovirus infection. J Gen Virol 82: 493-497.
18. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD (1994) Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 54: 2724-2730.
19. Dittmer D, Mocarski ES (1997) Human cytomegalovirus infection inhibits G1/S transition. J Virol 71: 1629-1634.
20. Bresnahan WA, Albrecht T, Thompson EA (1998) The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein. J Biol Chem 273: 22075-22082.
21. Elledge SJ, Richman R, Halls FL, Williamson RT, Lodgson N, Harper JW (1992) CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle. Proc Natl Acad Sci USA 89: 2907-2911.
22. Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE (1994) Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265: 391-394.
23. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908.
24. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM et al (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885-1893.
25. Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S et al (2005) Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11: 3385-3391.
26. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425: 407-410.
27. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L (2003) 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2: 123-129.
28. Yu Y, Alwine JC (2002) Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3′-OH kinase pathway and the cellular kinase Akt. J Virol 76: 3731-3738.
29. Yurochko AD, Kowalik TF, Huong SM, Huang E-S (1995) Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol 69: 5391-5400.